Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
20%(1 trials)

Phase Distribution

Ph phase_2
2
40%
Ph phase_1
3
60%

Phase Distribution

3

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
2(40.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(5)

Detailed Status

Completed5

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (60.0%)
Phase 22 (40.0%)

Trials by Status

completed5100%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_1

Mapatumumab, Cisplatin and Radiotherapy for Advanced Cervical Cancer

NCT01088347
completedphase_1

Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

NCT01258608
completedphase_2

A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung Cancer

NCT00583830
completedphase_2

Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma

NCT00315757
completedphase_1

A Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

NCT00712855

Clinical Trials (5)

Showing 5 of 5 trials
NCT01088347Phase 1

Mapatumumab, Cisplatin and Radiotherapy for Advanced Cervical Cancer

Completed
NCT01258608Phase 1

Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

Completed
NCT00583830Phase 2

A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung Cancer

Completed
NCT00315757Phase 2

Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma

Completed
NCT00712855Phase 1

A Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5